Please Wait a Moment
X

Articles

19Jul

FDA Releases ZIKV Guidance and Grifols ZIKV Assay Licensed- 1st Update

19 Jul, 2018 | Return|

This is the first update to the original CTS communication distributed on July 6th. As previously communicated, all CTS healthcare partners will remain on the Grifols ZIKV clinical trial until at least the end of October 2018, which coincides with the end of the WNV season.

Check out the Communication page for the complete details on the NAT ZIKV test update or by clicking the link: Communications

Related

Dr. Marion Lanteri Joins Creative Testing Solutions as Scientific Affairs VP

TEMPE, Ariz. (Sept. 8, 2022) — Marion Lanteri, Ph.D., began this week as Creative Testing Solu...

Read More >

National Blood Donor Month – January 2020

That’s just one of the reasons that National Blood Donor Month, which has taken place each Jan...

Read More >

Bio-Rad Geenius HIV 1/2 Implementation

CTS will implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The ...

Read More >

FDA Updates Emergency Use Authorization for COVID-19 Convalescent Plasma

On December 28, 2021, the FDA updated the emergency use authorization  (EUA) for COVID-19 conva...

Read More >

CTS to Implement Licensed Babesia testing

In response to the FDA guidance document for Babesia, CTS will implement the licensed Grifols  ...

Read More >

Spotlight on CTS AABB Annual Meeting Abstract Posters

CTS Spotlight at 2018 AABB Annual Meeting Sunday, October 14, 2018 at 1:30 PM: Scientific Oral ...

Read More >